§
Luxuse
Patent Intelligence
Sign In
← Back to Patent Explorer
US4906616A Expired / Lapsed US ⏱️ 0.0 years remaining

Hydrolyzed sodium casein compositions for dialysis procedures

Assignee: 3I Research Exploitation Ltd
•
Filing: 1989-02-06
•
Granted: 1990-03-06
•
Expires: 2009-02-06
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract A medicinal composition, particularly but not exclusively for use in fluids for medical dialysis, contains, as an agent for maintaining the osmolality of the fluid, a protein hydrolysate resulting from the action of a proteolytic enzyme on the sodium caseinate fraction of milk protein. The enzyme is preferably trypsin but other proteolytic enzymes and enzyme mixtures may be used, examples being chymotrypsin, pancreatin and pronase. The method of production involves treating the sodium caseinate in aqueous medium with the enzyme at the appropriate pH and temperature for optimum enzyme activity. The product of the enzymic hydrolysis, after filtration through a bacterial filter, adjustment of the osmolality to an appropriate level of around 300 mOsm/Kg and the pH to physiological level of about 6.6 and addition of physiological salt levels, constitutes the final product.

Inventors

  • 👤 Thomas Gilchrist
  • 👤 William Manson

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-23 19:30
CPC Classifications
A; A61; A61K; A61K38/00; A61K38/01; A61K38/012; A61K38/018; A61M; A61M1/00; A61M1/14; A61M1/16; A61M1/1654; A61M1/28; A61M1/287; Y; Y10; Y10S; Y10S530/00; Y10S530/827; Y10S530/832; Y10S530/833

Claims Analysis

Total Claims: 9
Claim 1
Independent Claim 59 words
In a dialysis process for removing water and biological toxins from body fluids by ultrafiltration wherein said body fluids contact a dialysis fluid through a semipermeable barrier, the improvement which comprises employing a peptide-containing proteolytic enzyme hydrolysate of sodium caseinate as an osmotic agent in the dialysis fluid, said hydrolysate being present in an amount effective to cause ultrafiltration.
Claim 2
Dependent Claim 59 words
In a dialysis process for removing water and biological toxins from body fluids by ultrafiltration wherein said body fluids contact a dialysis fluid through a semipermeable barrier, the improvement which comprises employing a peptide-containing proteolytic enzyme hydrolysate of sodium caseinate as an osmotic agent in the dialysis fluid, said hydrolysate being present in an amount effective to cause ultrafiltration.
Claim 3
Dependent Claim 39 words
A process according to claim 1 wherein the dialysis fluid additionally contains physiological salts, and a buffering agent, said salts and said agent being present in amounts effective to cause ultrafiltration of water and biological toxins into said fluid.
Claim 4
Dependent Claim 18 words
A process according to claim 1 wherein the proteolytic enzyme is trypsin, chymotrypsin, pancreatin, pronase or mixtures thereof.
Claim 5
Dependent Claim 21 words
A process according to claim 1 wherein the dialysis fluid has an osmolality of from about 100 to about 400 mOsm/Kg.
Claim 6
Dependent Claim 13 words
A process according to claim 4 wherein the osmolality is about 300 mOsm/Kg.
Claim 7
Dependent Claim 16 words
A process according to claim 1 wherein the dialysis fluid has a pH of about 6.6.
Claim 8
Dependent Claim 25 words
A process according to claim 2 wherein the physiological salts comprise ions selected from the group consisting of sodium, calcium, chloride, lactate, citrate and magnesium.
Claim 9
Dependent Claim 37 words
A process according to claim 7 wherein the concentration of the physiological salts is 135-145 meq/1 sodium ions, 2.2-2.5 meq/1 calcium ions, 90-100 meq/1 chloride ions, 33-35 meq/1 lactate ions, 0-2 meq/1 magnesium ions, and mixtures thereof.

References Cited (Backward Citations)

CA1039562A Cited
US4179338A Cited
US4427658A Cited
US4361587A Cited
US4495176A Cited
US4309417A Cited
US4462990A Cited
US4339433A Cited
WO1982003987A1 Cited
US4604379A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1993-03-05 1993-09-04 1994-03-06 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1997-03-05 1997-09-04 1998-03-06 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2001-03-05 2001-09-04 2002-03-06 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag